|

Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin

RECRUITINGN/ASponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
PhaseN/A
SponsorAssistance Publique - Hôpitaux de Paris
Started2024-02-15
Est. completion2026-02-15
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05977803

Summary

The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients \> 18 years of age
* Histologically proven primary lung cancer
* Histologically proven or not brain metastases
* Irradiated metastases
* Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy
* Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI
* Patients affiliated to a social security scheme

Exclusion Criteria:

* Opposition to the study
* Contraindication to MRI
* Refusal of imaging by the patient
* Patient with state medical aid (unless exemption from affiliation)
* Severe cognitive impairment making informed consent impossible
* Patients under guardianship or deprived of liberty

Conditions5

Brain MetastasesCancerLung CancerPulmonary CancerRadionecrosis

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.